로딩 중…
StockDiggingStockDigging

LeMaitre Vascular, Inc.

LMAT· NASDAQ
$103.54+2.19%
2026-08-03

Financials

Valuation Metrics

LeMaitre Vascular, Inc.'s Market Cap is $2.37B. At end of 2025 it was $1.84B. Ranked #1943 of 3,112 in US market (top 62%), #726 of 1,445 on NASDAQ (top 50%), #113 of 206 in Health Care Equipment & Services (top 55%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$2.37B
Revenue$256M
Net Income$62M
Total Assets$630M
Net Assets$407M
Employees646
Value
P/E37.91x
P/B5.82x
PEG0.89x
P/S9.23x
EV/EBITDA26.26x
FCF Yield3.34%
Profitability
ROE15.35%
ROA9.91%
Op. Margin28.51%
Revenue Growth11.16%
Earnings Growth42.39%
Financial Health
Debt Ratio54.82%
Total Debt$190M
FCF$79M
Cash$27M
Current Ratio14.32x
Net Debt/EBITDA1.69x
Dividend
Div. Yield0.82%
Div. Growth24.91%
Performance
1Y Return28.32%
1M Return0.64%
From 52W High-12.34%
1Y MDD-24.52%
Trading
Volume282,440 shares
Trading Value$29M
Per Share
EPS$2.54
BPS$17.33

Company Info

CEO Mr. George W. LeMaitre
Employees 646
HQ Burlington, United States

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.